"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM, 2016
Its simple, no-frills, and geared towards results
Studies have consistently shown that tirzepatide can provide more weight loss than single-agonist GLP-1 drugs like semaglutide (Ozempic and Wegovy), ranging around 20% lost weight over a years time on average
For example, Lemme GLP-1 Dailys website states that the product can promote your bodys GLP-1 production, reduce hunger and cravings, and support fat reduction with three clinically studied ingredients. However, their website points to studies in which the ingredients were investigated separately, in less than 200 participants
Kullanm rutini konusunda unu da eklememizde fayda var
In leave-one-out analyses, the pooled estimate remained in the same direction when omitting each study in turn (SMD range 1.36 to 0.82